References
- Norrby S R. Side-effect of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 378–383
- Schaad U B, Salam M A, Aujard Y, Dagan R, Green S DR, Peltola H, Rubio T T, Smith A L, Adam D. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995; 14: 1–9
- Boerema J BJ, Pauwels R, Scheepers J, Cromabach W. Efficacy and safety of pefloxacin in the treatment of patients with complicated urinary tract infections. J Antimicrob Chemother 1986; 17: 103–109, Suppl B
- Chevais M, Reinert P, Rondeau M C, Toblem R, Albengres E, Riant P, Tillement J P. Critical risk/benefit analysis of pefloxacin use in children under 15 years – the problem of arthralgias. Int J Clin Pharmacol Ther Toxicol 1987; 25: 306–309
- Pertuiset E, Lenoir G, Jehanne M, Douchan F, Guillot M, Menkes C J. Tolérance articulaire de la péfloxacine et de l'ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhumat 1989; 56: 735–740
- Bailey R R, Natale R, Linton A L. Nalidixic acid arthralgia. Can Med Assoc J 1972; 107: 604–605
- Stahlmann R, Merker H J, Hinz N, Chahoud I, Webb J, Heger W, Neubert D. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch Toxicol 1990; 64: 193–204
- Schaad U B, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991; 10: 723–729
- Schaad U B, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992; 11: 1047–1049